Identification of Cytoskeletal [ 14 C ] Carboplatin-Binding Proteins Reveals Reduced Expression and Disorganization of Actin and Filamin in Cisplatin-Resistant Cell Lines
D. Shen,Xing-jie Liang,M. Gawinowicz,M. Gottesman
Abstract:Cisplatin resistant (CP-r) cells often show decreased uptake of cisplatin in association with reduced cell surface proteins and decreased endocytosis. In this report, two major [C]carboplatin-binding proteins were identified as filamin and actin by photoaffinity labeling and mass spectrometry. Decreased expression of these two proteins was found in two different human CP-r cell lines (KB-CP20 and 7404-CP20), in comparison with their parental cell lines (KB-3-1 and BEL-7404), respectively. Disorganization of -actin and filamin 250 and 90 was also detected in these CP-r cells by confocal microscopy. Transfection of a wild-type actin-enhanced green fluorescent protein (EGFP) expression vector into 7404-CP20 cells resulted in a nonfilamentous actin-EGFP distribution compared with a normal distribution in the cisplatin-sensitive BEL-7404 cells, suggesting that cytoskeletal organization is disturbed in the CP-r cells. The identification of actin and filamin as [C]carboplatin-binding proteins and decreased expression and disorganization of several cytoskeletal proteins in CP-r cells provide a molecular and cellular basis for the known defect in endocytosis in these cells. Cisplatin (cis-diamminedichloroplatinum II) has become a major chemotherapeutic agent for treatment of a wide spectrum of solid tumors; however, the ability of cancer cells to become resistant to the drug remains a significant impediment to successful chemotherapy. Intensive efforts have been made through biochemical characterization and cellular and molecular approaches to identify the basis of resistance and define genes that are involved in acquisition of cisplatin resistance (Fojo, 2001; Niedner et al., 2001; Deverman et al., 2002; Siddik, 2002; Gottesman et al., 2003). One of the most consistent features observed in cisplatinresistant (CP-r) cells both in vivo and in vitro is the reduced accumulation of the drug and other related chemicals (Shen et al., 2000). We have previously reported that a pleiotropic defect resulting in reduced accumulation of [H]methotrexate, As and As in the CP-r cells was found to be associated with reduced expression of folate-binding protein and arsenic-binding proteins (Shen et al., 1998). We recently found defective fluid-phase endocytosis and mislocalization to the cytoplasm of several cell surface proteins, such as folate-binding protein and multidrug resistance-associated proteins in human CP-r cell lines (Chauhan et al., 2003; Liang et al., 2003); however, the cell biology and molecular bases of these features remain unclear. To investigate the cellular and biochemical events involved in cisplatin resistance, photoaffinity labeling was applied in the current work to trace the pathway of [C]carboplatin entering cells as a powerful tool to detect intracellular molecules with which platinum compounds might interact during the uptake process. Two [C]carboplatin-binding proteins (actin and filamin) were identified as elements of the cytoskeleton involved in endocytosis, both of which were down-regulated in CP-r cell lines. In addition, reduced expression of -tubulin, keratin, and dynamin 2 were also detected in the CP-r cells. Defects in the cytoskeleton, revealed initially by UV cross-linking of [C]carboplatin, may be an important component of the pleiotropic phenotype found in CP-r cells. Materials and Methods Cell Lines and Cell Culture. Two populations of CP-r cell lines and their parental cell lines were studied: the human epidermoid carcinoma cell line KB-3-1 and its CP-r derivative, KB-CP20, and the human liver carcinoma cell line BEL-7404 and its CP-r derivative 7404-CP20. Both human CP-r cell lines were selected in several steps up to 20 g of cisplatin/ml of medium as described previously This work was supported by the National Institutes of Health. ABBREVIATIONS: CP-r, cisplatin-resistant; CP-s, cisplatin-sensitive; PAGE, polyacrylamide gel electrophoresis; EGFP, enhanced green fluorescent protein; MALDI-MS, matrix-assisted laser desorption ionization-mass spectrometry. 0026-895X/04/6604-789–793 MOLECULAR PHARMACOLOGY Vol. 66, No. 4 U.S. Government work not protected by U.S. copyright 3238/1174168 Mol Pharmacol 66:789–793, 2004 Printed in U.S.A. 789 at A PE T Jornals on July 0, 2017 m oharm .aspeurnals.org D ow nladed from (Shen et al., 2000). All cell lines were grown as monolayer cultures at 37°C in 5% CO2, using Dulbecco’s modified Eagle’s medium with 4.5 g/l glucose (Invitrogen, Carlsbad, CA), supplemented with l-glutamine, penicillin, streptomycin, and 10% fetal bovine serum (Cambrex Bio Science Walkersville Inc., Walkersville, MD). Preparation of Enriched Plasma Membrane Proteins and Whole Cell Lysates. Membrane proteins were purified according to the method of Cornwell et al. (1987). In brief, 1 10 cells from each cell line were disrupted on ice by nitrogen cavitation with constant stirring for 40 min. Two cycles of sucrose gradient ultracentrifugation were followed. The purified membrane pellets were re-suspended in 3 ml of TSNa buffer (10 mM Tris-HCl, pH 7.45, 250 mM sucrose, 50 mM NaCl, and 1% aprotinin) and stored at 80°C until use. For whole cell lysates, cells were lysed in a lysis buffer [50 mM Tris-HCl, pH 8.0, 140 mM NaCl, 1.5 mM MgCl2, and 0.5% (v/v) Nonidet P-40], then centrifuged at 2000 rpm for 5 min to discard the nucleus. Radiochemical Photoaffinity Labeling and Mass Peptide Spectrometric Mapping. [C]Carboplatin was purchased from Amersham Biosciences Inc. (Piscataway, NJ). Ultraviolet irradiation was applied as described previously (Shen et al., 1998). In brief, a 200 W mercury lamp was used as a light source at a distance of 6 to 8 cm from microtubes containing a mixture of 100 g of enriched plasma membrane proteins in 15 mM HEPES, 150 mM mannitol, 1 mM MnCl2, and 1 mM phenylmethylsulfonyl fluoride with 4 Ci of [C]carboplatin on ice for 15 min. After UV cross-linking, the proteins were separated on SDS-PAGE, and enhanced with FluoroHance (Research Products International, Mount Prospect, IL) and then exposed to X-ray film (BioMax MR; Eastman Kodak, Rochester, NY) at 80°C for the desired period of time. [C]Carboplatin-labeled protein bands of interest were excised from a dried gel. After reduction and alkylation with iodoacetamide, the proteins were digested with trypsin and then analyzed on a Voyager DE RP mass spectrometer in the linear mode. Antibodies and Immunoblotting. Antibodies directed to actin, filamins, dynamin, tubulin, keratin, and EEA1 were purchased from BD Biosciences PharMingen (San Diego, CA) unless otherwise noted. SDS-PAGE immunoblotting was carried out as described previously (Shen et al., 1998). Minigels were run as recommended by the manufacturer (Invitrogen). After electrophoresis, the gels were transblotted onto nitrocellulose membranes (Schleicher & Schuell, Keene, NH) at 4°C. Immunoreaction was performed with desired primary antibodies and secondary horseradish peroxidase-conjugated antibodies (Jackson ImmunoResearch Laboratories, West Grove, PA). Pierce enhanced chemiluminescence reagents (Pierce Chemical, Rockford, IL) were used for developing signals as described by the manufacturer. Confocal Image Analysis. Cells were cultured in a Lab-Tek Chamber Slide (Nalge Nunc International, Naperville, IL), and fixed with 70% ETOH at 20°C for 15 min. The fixed cells were reacted with the primary antibodies and then followed by rhodamine-labeled anti-mouse IgG secondary antibody. Fluorescein isothiocyanatephalloidin (Molecular Probes, Eugene, OR) was used for direct staining of actin on fixed cells. Immunofluorescent images of cells were monitored under a laser-scanning confocal microscope (Bio-Rad, Hercules, CA) at 600 magnification. Actin-pEGFP Expression Vector and Transient Transfection. The expression vector for actin-pEGFP (actin fused to enhanced green fluorescent protein) was purchased from BD Biosciences Clontech, (Palo Alto, CA). Transient transfection of this vector into BEL-7404 and 7404-CP20 cells was performed using a LipofectAMINE reagent kit (Invitrogen) according to the manufacturer’s instructions. Results and Discussion In this study, our goal was to trace the uptake pathway of a platinum compound in cells by comparing binding in wild-type cells and cells with a defect in uptake. [C]Carboplatin was used in combination with UV cross-linking to determine whether there are any cellular proteins that differentially bind this radioactively labeled compound in sensitive and resistant cells. Figure 1 shows that two bands at Mr 230,000 (P230) and Mr 45,000 (P45) that are labeled with [C]carboplatin are markedly reduced in both CP-r KB-CP20 and 7404-CP20 cells compared with their parental KB-3-1 and BEL-7404 cell lines, respectively. To identify these two [C]carboplatin-binding proteins, these protein bands were excised and then analyzed by mass peptide spectrometric mapping as described under Materials and Methods. Figure 2, A and B, shows the mass spectra generated from tryptic digestion of these two peptides (P230 and P45) by MALDI-MS. The polypeptides were identified as filamin for P230 and actin for P45, respectively (Table 1). To further confirm the identification of these two [C]carboplatin-binding proteins, immunofluorescence confocal microscopic observation was performed using fluorescent phalloidin for actin and monoclonal antibodies directed to filamin 90 and filamin 250. Figure 3 shows that expression of actin and filamins (Mr 90,000 and Mr 250,000) was decreased in the CP-r cells compared with their parental cisplatin-sensitive (CP-s) cells. Furthermore, the distribution and arrangement of -actin, filamin 90, and filamin 250 were significantly changed in the CP-r cells as shown in Fig. 3 (bottom). A well defined intracellular microfilament fiber network was displayed in the CP-s cells (Fig. 3, top), whereas fewer structural microfilaments occurred in the CP-r cells (Fig. 3, bottom). The reduced expression of Fig. 1. [C]Carboplatin labeling of